WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018064013) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/064013    International Application No.:    PCT/US2017/053370
Publication Date: 05.04.2018 International Filing Date: 26.09.2017
IPC:
G01N 33/574 (2006.01), C07K 16/28 (2006.01), G01N 33/92 (2006.01)
Applicants: ONCOLOGIE, INC. [US/US]; P.O. Box 650022 West Newton, Massachusetts 02465 (US)
Inventors: TANG, Min; (US).
SHAN, Joseph, S.; (US).
KING, Steven, W.; (US).
CHANG, Connie; (US).
BROWN, Michael, A.; (US)
Agent: COLLAZO, Diana M.; (US)
Priority Data:
62/480,994 03.04.2017 US
62/406,727 11.10.2016 US
62/507,580 17.05.2017 US
62/400,549 27.09.2016 US
Title (EN) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
(FR) PROCÉDÉ DE TRAITEMENT DU CANCER À L'AIDE DE BAVITUXIMAB SUR LA BASE DE NIVEAUX DE β2-GLYCOPROTÉINE 1, ET DOSAGES ASSOCIÉS
Abstract: front page image
(EN)Disclosed are surprising new methods and kits for identifying and treating patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and bavituximab combination therapies. The methods and kits are based on the surprising finding that defined ranges of pre-treatment blood concentrations of β2-glycoprotein 1 (β2GΡΙ), particularly functional β2GPI, act as an indicator to accurately predict patients with better treatment outcomes.
(FR)L'invention concerne de nouveaux procédés et kits surprenants permettant l'identification et le traitement de patients pouvant être traités à l'aide d'anticorps ciblant PS, en particulier permettant l'identification et le traitement de patients atteints d'un cancer au moyen de thérapies au bavituximab et combinées au bavituximab. Les procédés et les kits sont basés sur la découverte surprenante selon laquelle des plages définies de concentrations sanguines de pré-traitement de la β2-glycoprotéine 1 (β2GΡΙ), en particulier la β2GPI fonctionnelle, agissent en tant qu'indicateur pour prédire avec précision quels patients présentent de meilleurs résultats thérapeutiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)